Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DDX3X | O00571 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236591 | 0.89 | PKM (0.53) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4233910 | 0.87 | MEN1 (0.54) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4235514 | 0.84 | MEN1 (0.56) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4686933 | 0.84 | KMT2A (0.65) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4686928 | 0.84 | KMT2A (0.65) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4239097 | 0.83 | PKM (0.45) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL4228345 | 0.82 | MAPT (0.53) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4786650 | 0.82 | TBXA2R (0.61) | MEN1KMT2AMAPTTBXA2R | |
| SCHEMBL4229236 | 0.82 | KMT2A (0.44) | MEN1KMT2AMAPTHTTMAPK1 | |
| SCHEMBL4233889 | 0.78 | KMT2A (0.52) | MEN1KMT2AMAPTHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MEN1 2447/4885KMT2A 3436/4885MAPT 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.